BioNTech (NASDAQ:BNTX) Price Target Cut to $122.00 by Analysts at TD Cowen

BioNTech (NASDAQ:BNTX - Free Report) had its price objective decreased by TD Cowen from $132.00 to $122.00 in a research note issued to investors on Tuesday morning, Benzinga reports. TD Cowen currently has a hold rating on the stock.

A number of other equities analysts have also recently weighed in on BNTX. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Hsbc Global Res upgraded BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. HSBC increased their price objective on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and boosted their price target for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $125.00 to $124.00 and set a "neutral" rating on the stock in a research report on Monday. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $134.69.

BioNTech Stock Up 1.8 %

Shares of NASDAQ BNTX traded up $2.00 during trading on Tuesday, reaching $110.97. 417,515 shares of the stock were exchanged, compared to its average volume of 782,042. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The business's 50-day moving average price is $110.15 and its 200 day moving average price is $96.06. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $26.39 billion, a price-to-earnings ratio of -48.95 and a beta of 0.26.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm's revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.73 earnings per share. As a group, equities analysts forecast that BioNTech will post -2.93 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently modified their holdings of the stock. Covestor Ltd grew its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock worth $41,000 after buying an additional 238 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after purchasing an additional 252 shares in the last quarter. Blue Trust Inc. boosted its holdings in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after buying an additional 388 shares during the last quarter. Finally, Crewe Advisors LLC purchased a new stake in shares of BioNTech during the first quarter worth approximately $75,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.